早龄筛查中粪便免疫化学检测的长期有效性
该研究分析台湾40至49岁社区居民筛查队列,比较40至49岁起始粪便免疫化学检测(FIT)筛查与50岁起始全国常规筛查对结直肠癌发病和死亡的影响。早期筛查组结直肠癌发病率和死亡率均低于常规筛查组,倾向评分匹配及扩展不依从调整后结果一致。
要点
- 40至49岁起始FIT筛查与结直肠癌发病率和死亡率进一步降低相关。
- 倾向评分匹配分析中早期筛查显著降低结直肠癌发病率(aRR 0.79)和死亡率(aRR 0.61)。
- 扩展不依从调整模型中发病率降低25%、死亡率降低34%。
核心结论
- 与50岁起始筛查相比,40至49岁起始FIT筛查与结直肠癌死亡率和发病率进一步降低相关,作者认为这为降低结直肠癌筛查起始年龄提供了有力的实证支持。
研究设计与样本
- 研究分析台湾40至49岁社区居民筛查队列,按是否参加早期筛查(40至49岁)及是否继续全国常规筛查(50岁及以上)分为4个亚队列,随访至2019年比较结直肠癌发病率和死亡率。
- 为减轻自选择偏倚,采用延迟筛查设计和高效倾向评分匹配,分析限于参加常规筛查的参与者;并对全部4个亚队列应用扩展不依从调整以验证结果。
- 数据收集时间为2001年1月至2019年12月,数据分析时间为2021年1月至2024年12月。
主要发现
- 共纳入263 125名参与者,其中女性146 796名(55.8%);39 315名参加早期和常规筛查,223 810名仅参加常规筛查。
- 早期筛查组结直肠癌发病率低于常规筛查组(26.1[95%CI,22.3-29.9] vs 42.6[95%CI,40.5-44.7]/10万人年),死亡率亦低于常规筛查组(3.2[95%CI,1.9-4.6] vs 7.4[95%CI,6.5-8.2]/10万人年)。
- 倾向评分匹配分析中,早期筛查显著降低结直肠癌发病率(aRR 0.79;95%CI,0.67-0.94)和死亡率(aRR 0.61;95%CI,0.38-0.98)。
- 扩展不依从调整模型中结果一致,发病率降低25%(aRR 0.75;95%CI,0.72-0.77),死亡率降低34%(aRR 0.66;95%CI,0.62-0.71)。
关键数值与推荐
- 早期筛查组自40至49岁起始每两年一次FIT筛查,常规筛查组自50岁起始,随访在台湾全国筛查项目下继续。
- 主要结局为结直肠癌发病率和死亡率,以每10万人年病例数报告,并以调整相对危险度(aRR)比较早期筛查组与常规筛查组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The rising incidence of young-onset colorectal cancer (CRC) has prompted health policymakers to consider lowering the recommended starting age for screening. However, population-based evidence supporting the long-term effectiveness of early-age screening remains limited. OBJECTIVE: To evaluate whether initiating fecal immunochemical test (FIT) screening at ages 40 to 49 years, rather than at the currently recommended age of 50 years, reduces CRC incidence and mortality. DESIGN, SETTING, AND PARTICIPANTS: This study analyzed a community-based screening cohort of Taiwanese residents aged 40 to 49 years, categorized into 4 subcohorts based on participation in early screening (age 40 to 49 years) and continuation of nationwide regular screening (50 years and older). The cohort was followed up until 2019 to compare CRC incidence and mortality across subcohorts. To mitigate self-selection bias, a delayed screening design and efficient propensity score matching was used, restricting analyses to participants attending regular screening. To validate the findings, an extended nonadherence adjustment was applied to all 4 subcohorts. Data were collected from January 2001 to December 2019, and data were analyzed from January 2021 to December 2024. EXPOSURES: Biennial FIT screening was initiated for the early screening group at ages 40 to 49 years and for the regular screening group at age 50 years, with follow-up continuing under Taiwan's national screening program. MAIN OUTCOMES AND MEASURES: Primary outcomes were CRC incidence and mortality rates, reported as cases per 100 000 person-years, with adjusted relative risks (aRRs) comparing early vs regular screening groups. RESULTS: Of 263 125 included participants, 146 796 (55.8%) were female. A total of 39 315 participated in early and regular screening, and 223 810 participated in regular screening only. The early screening group exhibited lower CRC incidence (26.1 [95% CI, 22.3-29.9] vs 42.6 [95% CI, 40.5-44.7] per 100 000 person-years) and mortality (3.2 [95% CI, 1.9-4.6] vs 7.4 [95% CI, 6.5-8.2] per 100 000 person-years). In propensity score-matched analyses, early screening significantly reduced CRC incidence (aRR, 0.79; 95% CI, 0.67-0.94) and mortality (aRR, 0.61; 95% CI, 0.38-0.98). Findings were consistent in the extended nonadherence adjustment model, showing a 25% reduction in incidence (aRR, 0.75; 95% CI, 0.72-0.77) and a 34% reduction in mortality (aRR, 0.66; 95% CI, 0.62-0.71). CONCLUSIONS AND RELEVANCE: This study found that initiating FIT screening at age 40 to 49 years was associated with further reduction in CRC mortality and incidence compared with starting screening at age 50 years. These results provide strong empirical support for lowering the CRC screening age, with substantial public health implications.
引用
- Chiu HM, Chen SL, Su CW, et al. Long-Term Effectiveness Associated With Fecal Immunochemical Testing for Early-Age Screening. JAMA Oncol. 2025. PMID: 40504543. doi:10.1001/jamaoncol.2025.1433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。